Capital Wealth Planning LLC Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Capital Wealth Planning LLC lowered its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 30.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 803,685 shares of the company’s stock after selling 356,962 shares during the period. Johnson & Johnson makes up 3.0% of Capital Wealth Planning LLC’s investment portfolio, making the stock its 19th largest position. Capital Wealth Planning LLC’s holdings in Johnson & Johnson were worth $137,487,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. US Asset Management LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $30,000. Steward Financial Group LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $34,000. Jackson Wealth Management LLC grew its position in Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock valued at $40,000 after buying an additional 277 shares during the period. Iron Horse Wealth Management LLC lifted its holdings in Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $45,000 after purchasing an additional 61 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Johnson & Johnson by 290.7% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock valued at $47,000 after purchasing an additional 218 shares in the last quarter. 67.84% of the stock is owned by institutional investors and hedge funds.

Shares of JNJ stock opened at $180.10 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.35 and a quick ratio of 1.12. The firm’s 50-day moving average is $172.50 and its two-hundred day moving average is $168.01. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $184.20. The company has a market capitalization of $473.53 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 2.71 and a beta of 0.72.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, topping analysts’ consensus estimates of $2.61 by $0.06. Johnson & Johnson had a net margin of 22.26% and a return on equity of 37.46%. The company had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. During the same period in the previous year, the firm earned $2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.0% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.48 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.51%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 54.29%.

Several equities analysts have issued reports on JNJ shares. StockNews.com started coverage on shares of Johnson & Johnson in a report on Thursday, March 31st. They set a “strong-buy” rating on the stock. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Raymond James raised their price target on shares of Johnson & Johnson from $185.00 to $195.00 and gave the stock an “outperform” rating in a research note on Thursday, April 14th. Finally, Bank of America assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating on the stock. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $184.57.

In other Johnson & Johnson news, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Profile (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.